Forgot your password?
The drug already holds approvals for indications including atopic dermatitis
More than 26 million people in the US are currently living with the inflammatory skin condition
The candidate has already been granted FDA fast track designation for atopic dermatitis
Around 70% of patients with severe cases report problems performing everyday activities
Approximately 40% of atopic dermatitis patients have moderate or severe symptoms
The company will also have an opportunity to evaluate Spevigo in additional skin conditions
The drug is now the only targeted medicine approved in the US to treat the skin disease
As many as 181,000 people in the US are affected by the chronic skin disorder
It is hoped that the approval will support treatment continuity for patients
The decision gives patients access to a therapy that targets the interleukin-36 pathway for the first time